Serum endocan levels in patients with chronic liver disease

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 7, 2014, Pages 1802-1807

  Tok, Duran ^a   Ekiz, Fuat ^b   Basar, Omer ^c   Coban, Sahin ^d   Ozturk, Gulfer ^d  

^a Turkish Armed Forces Health Command   (Turkey)

^b ANTAKYA STATE HOSPITAL   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d Department of Gastroenterology Dişkapi Education and Research Hospital ^*  (Turkey)

Author keywords

Chronic hepatitis B; Chronic hepatitis C; Endocan; Non alcoholic fatty liver disease

Indexed keywords

EID: 84905644959     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Boyer TD, Manns MP, Sanyal AJ. Hepatic fibrosis and cirrhosis. In: Rockey DC, Friadman SL, editors. Zakim and boyer's hepatology. Philadelphia: Saunders; 2006. pp. 87-109.
2. Rossi E, Adams LA, Bulsara M, Jeffrey GP. Assessing liver fibrosis with serum marker models. Clin Biochem Rev 2007; 28: 3-10.
3. Kershenobich Stalnikowitz D, Weissbrod AB. Liver fibrosis and inflammation. A review. Ann Hepatol 2003; 2: 159-63.
4. Başar O, Akbal E, Köklü S, Koçak E, Tuna Y, Ekiz F, Gültuna S, Yιlmaz FM, Aydoǧan T. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand J Clin Lab Invest 2012 Oct; 72: 479-83.
5. Başar O, Yimaz B, Ekiz F, Giniş Z, Altinbaş A, Aktaş B, Tuna Y, Çoban S, Delibaş N, Yüksel O. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013 Apr; 37: 152-8.
6. Ekiz F, Yüksel O, Koçak E, Yi{dotless}lmaz B, Alti{dotless}nbaş A, Çoban S, Yüksel I, Üsküdar O, Köklü S. Mean platelet volume as a fibrosis marker in patients with chronic hepatitis B. J Clin Lab Anal 2011; 25: 162-5.
7. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25-37.
8. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, Celik T, Turker T, Iyisoy A. Endocan--A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension: A Pilot Study. Angiology 2014 Jan 8; [Epub ahead of print].
9. The French METAVIR Cooperative Study Group. 374 Intraobserver and interobserver variations in liver biopsy 375 interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
10. Hamaguchi M, Kojima T, Itoh Y Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in Non-alcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-2715
11. Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, Cakar M, Kucuk U, Eksioglu M, Kurt YG. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014; 70: 291-6.
12. Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc JF, Sturm N, Bioulac-Sage P, Nahon P, Nault JC, Charnaux N, N'kontchou G, Trinchet JC, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-Carrié N. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol 2013 Dec; 59: 1264-70.
13. Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, Kurt O, Kurt YG, Aydin I, Kilic S. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013 Nov; 169: 1066-70.
14. Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev 2013 Aug; 22: 1343-52.